Actively Recruiting
The Application of Continuous Blood Glucose Monitoring in Optimizing the Management of Early Onset and Late Onset Type 2 Diabetes: an Effectiveness - Implementation Type II Hybrid Design Quasi-experimental Pragmatic Trial
Led by Peking University · Updated on 2025-07-31
600
Participants Needed
2
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the use of continuous glucose monitoring (CGM) technology for managing type 2 diabetes in community healthcare settings in China. Type 2 diabetes poses a major public health challenge, and traditional blood glucose monitoring methods have limitations such as patient discomfort and delayed data sharing with healthcare providers. This study uses a quasi-experimental pragmatic trial design to assess CGM effectiveness and implementation in Chinese adults with type 2 diabetes. Participants include 800 adults randomly assigned to either a CGM intervention group or a control group using traditional blood glucose monitoring. The CGM group receives training and wears CGM devices for three separate 2-week periods over 24 weeks, supported by an integrated data platform and standardized healthcare protocols. The control group continues usual self-monitoring blood glucose practices and routine medical care with flexibility in medication and lifestyle adjustments. Throughout the 24-week study, researchers will measure changes in glycated hemoglobin (HbA1c) and other metabolic markers, patient satisfaction, and quality of life. Data collection includes repeated glucose measurements, healthcare provider and participant surveys, and qualitative interviews to explore implementation barriers and facilitators. The study tracks treatment costs and quality of life to inform strategies for improving diabetes care in community settings.
CONDITIONS
Brief Title
The Application of Continuous Blood Glucose Monitoring in Optimizing the Management of Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Previously diagnosed with type 2 diabetes for at least 1 year in the specified electronic medical record systems
- Permanent resident registered and with health records filed in Yinzhou District
You will not qualify if you...
- Pregnant women
- Diagnosis of type 1 diabetes, adult latent autoimmune diabetes, or special types of diabetes (such as post pancreatic surgery or monogenic diabetes)
- Current or previous use of hormone drugs affecting blood sugar levels
- Severe kidney insufficiency (eGFR less than 30 ml/min/1.73 m2 or undergoing hemodialysis)
- Severe liver dysfunction (ALT or AST more than 3 times the upper limit of normal)
- Patients with tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 weeks
Participants receive continuous blood glucose monitoring assisted blood glucose management including individualized health education, device setup, and integration with healthcare systems.
Visits at baseline, week 8, week 16, and week 24 for assessments and device use periods
Trial Site Locations
Total: 2 locations
1
Qianhu Hospital
Ningbo, Zhejiang, China
Actively Recruiting
2
Fuming Street Community Health Service Center
Ningbo, China
Actively Recruiting
Research Team
Y
Yunxiao Wu
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here